It was the third trigger of the recession indicator in less than two weeks.Bondsread more
U.S. manufacturer growth slowed to the lowest level in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
Philadelphia Fed President Patrick Harker said he doesn't see the case for additional stimulus after the Federal Reserve's July rate cut.The Fedread more
Stocks fell as fears of an economic recession built up ahead of a key speech from Federal Reserve Chairman Jerome Powell.US Marketsread more
"My sense was we've added accommodation, and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Former Prudent Bear Fund manager David Tice is urging investors to brace for a massive downturn.Trading Nationread more
German Chancellor Angela Merkel said a solution to the Irish "backstop" is possible before the October 31 Brexit deadline.Europe Economyread more
Apple plans to unveil three new iPhones in September, including two new "Pro" models and a successor to the iPhone XR, Bloomberg reported Thursday.Technologyread more
A ruling against J&J could mean more big payouts in similar cases across the country.Health and Scienceread more
While Volkswagen may not want to invest in Tesla, the U.S. carmaker has been scouting locations in Europe for a new Gigafactory there.Autosread more
Corporate profits posted modest growth in the second quarter as companies brace for slowing global growth.Retailread more
Shares of Agios Pharmaceuticals briefly popped more than 8 percent Monday after reporting encouraging data on its lead drug, AG-348, which could treat a rare inherited disease called PK deficiency — a disease characterized by accelerated destruction of red blood cells.
The stock ended the day up more than 3 percent.
The data were presented in a Saturday report.
"People with PK deficiency suffer from chronic anemia and a range of other complications brought on by both their disease and existing supportive therapies, including blood transfusions and splenectomy," noted Dr. Rachael Grace, a principal investigator for the study, in the report.
"These data are exciting for the hematology community and patients, as they demonstrate the potential for AG-348 to provide the first disease-modifying treatment with impressive and prolonged increases in hemoglobin levels," she said.
As of March 27, 18 patients had been treated with AG-348 for at least three weeks, Agios said. Three of the 18 patients had completed 24 weeks of treatment with either 50 or 300 milligrams twice daily, according to the report.
The drug developer is also testing another drug, AG-519, for the same disease.
Agios stock has fallen sharply this year, down nearly 20 percent.